228 related articles for article (PubMed ID: 18932097)
21. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma.
Clarke JL
Semin Radiat Oncol; 2014 Oct; 24(4):273-8. PubMed ID: 25219812
[TBL] [Abstract][Full Text] [Related]
23. Fewer dollars, more sense.
Garfield DH; Hercbergs A
J Clin Oncol; 2008 Nov; 26(32):5304-5; author reply 5305. PubMed ID: 18854564
[No Abstract] [Full Text] [Related]
24. Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity.
Takano S; Mashiko R; Osuka S; Ishikawa E; Ohneda O; Matsumura A
Brain Tumor Pathol; 2010 Oct; 27(2):89-94. PubMed ID: 21046310
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series.
Zustovich F; Ferro A; Farina P
Clin Genitourin Cancer; 2014 Jun; 12(3):e107-10. PubMed ID: 24583162
[No Abstract] [Full Text] [Related]
26. Re: angiogenesis and antiangiogenic therapy for malignant gliomas.
Kepes JJ
Brain Tumor Pathol; 2005; 22(1):51. PubMed ID: 18095105
[No Abstract] [Full Text] [Related]
27. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
Sherman JH; Aregawi DG; Lai A; Fathallah-Shaykh HM; Bierman PJ; Linsky K; Larner JM; Newman SA; Schiff D
Neurology; 2009 Dec; 73(22):1924-6. PubMed ID: 19949039
[No Abstract] [Full Text] [Related]
28. Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?
Gerstner ER; Emblem KE; Sorensen GA
Cancer J; 2015; 21(4):337-42. PubMed ID: 26222087
[TBL] [Abstract][Full Text] [Related]
29. World's first delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients.
Expert Rev Anticancer Ther; 2010 Jan; 10(1):5. PubMed ID: 20014880
[No Abstract] [Full Text] [Related]
30. [Topics for antiangiogenic therapy for glioblastoma].
Takano S; Matsumura A
No Shinkei Geka; 2012 Jun; 40(6):481-502. PubMed ID: 22647508
[No Abstract] [Full Text] [Related]
31. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies.
Field KM; Jordan JT; Wen PY; Rosenthal MA; Reardon DA
Cancer; 2015 Apr; 121(7):997-1007. PubMed ID: 25263092
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic agents in breast cancer.
Salter JT; Miller KD
Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
[No Abstract] [Full Text] [Related]
33. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
[TBL] [Abstract][Full Text] [Related]
34. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
Lomax AJ; Hill PA; Ashley DM
J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
[TBL] [Abstract][Full Text] [Related]
35. Antiangiogenic therapy for glioblastoma.
Gerstner ER; Batchelor TT
Cancer J; 2012; 18(1):45-50. PubMed ID: 22290257
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.
Lombardi G; Pambuku A; Bellu L; Farina M; Della Puppa A; Denaro L; Zagonel V
Crit Rev Oncol Hematol; 2017 Mar; 111():94-102. PubMed ID: 28259301
[TBL] [Abstract][Full Text] [Related]
37. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Mrugala MM
Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
[No Abstract] [Full Text] [Related]
39. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Chamberlain MC
Neurology; 2009 Feb; 72(8):772-3; author reply 773-4. PubMed ID: 19237713
[No Abstract] [Full Text] [Related]
40. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
Mason JO; Albert MA; Mays A; Vail R
Retina; 2006 Sep; 26(7):839-41. PubMed ID: 16963866
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
